Literature DB >> 2285297

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.

K V Rolston1, M Messer, D H Ho.   

Abstract

The in vitro susceptibilities of three Pseudomonas species (Pseudomonas aeruginosa, Pseudomonas putida, and Pseudomonas fluorescens) and Xanthomonas maltophilia to quinolone antimicrobial agents were determined. Several newer agents, particularly PD117558, PD117596, PD127391, sparfloxacin (AT-4140), A-56620, and temafloxacin, were active against Pseudomonas species. X. maltophilia isolates were generally less susceptible than were Pseudomonas isolates but were inhibited by some of the newer quinolones.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2285297      PMCID： PMC171934          DOI： 10.1128/AAC.34.9.1812

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro evaluation of A-56619 and A-56620, two new quinolones.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.

Authors:  M Asahara; A Tsuji; S Goto; K Masuda; A Kiuchi
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Comparative in vitro activity of a new quinolone, AM-1091.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Intravenous ciprofloxacin for infections in cancer patients.

Authors:  K V Rolston; E Haron; C Cunningham; G P Bodey
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.

Authors:  H C Neu; N X Chin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

6.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

7.  The in-vitro activity of PD127,391, a new quinolone.

Authors:  A King; C Boothman; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

8.  In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.

Authors:  T Kumada; H C Neu
Journal:  J Antimicrob Chemother       Date:  1985-11       Impact factor: 5.790

9.  Pseudomonas bacteremia. Retrospective analysis of 410 episodes.

Authors:  G P Bodey; L Jadeja; L Elting
Journal:  Arch Intern Med       Date:  1985-09

10.  Pseudomonas putida. Newly recognized pathogen in patients with cancer.

Authors:  E Anaissie; V Fainstein; P Miller; H Kassamali; S Pitlik; G P Bodey; K Rolston
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965
View more
  9 in total

1.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

2.  In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia.

Authors:  T A Ristow; L R Peterson; J B Kahn
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model.

Authors:  M W Garrison; D E Anderson; D M Campbell; K C Carroll; C L Malone; J D Anderson; R J Hollis; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.

Authors:  R Paton; R S Miles; S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  C D Poulos; S O Matsumura; B M Willey; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.